Combination of Tiragolumab, Atezolizumab, and Chemotherapy in Treating Advanced Nonsquamous Non–Small Cell Lung Cancer: A Phase Study

1

Non–small cell lung cancer (NSCLC) represents about 85% of lung cancer cases and is the leading cause of cancer mortality globally.
2

TIGIT is an immune checkpoint receptor that, when activated, limits T cell and NK cell function, contributing to poor outcomes in NSCLC.
3

The SKYSCRAPER-06 trial evaluated the efficacy and safety of tiragolumab plus atezolizumab and chemotherapy versus pembrolizumab plus chemotherapy.
4

Eligible patients were those with untreated advanced nonsquamous NSCLC, excluding those with EGFR alterations or ALK rearrangements.
5

The study followed Good Clinical Practice guidelines and was approved by institutional review boards at participating centers.

Jama Oncology

by Mark A. Socinski, Rolf Stahel, Dae Ho Lee, Federico Cappuzzo, Makoto Nishio, Christine M. Lovly, Ozgur Ozyilkan, Qingshan Li, Melissa Johnson, Edward B. Garon, Saadettin Kilickap, Flavio Augusto Ferreira da Silva, Jorge Alatorre-Alexander, Raymond Meng, Reena Amin, Christina Matheny, Sarah Troutman, Xiaohui Wen, Namrata S. Patil, Wei Zou, Delvys Rodriguez-Abreu
June 1, 2026

1